Business context and reporting period
Filing identity: The request identifies Solana Co, but the supplied Form 10-Q is for Helius Medical Technologies, Inc. (Nasdaq: HSDT), for the quarter ended September 30, 2021; it was filed November 9, 2021. The summary below reflects the filing provided.
Helius develops non-invasive neurological technologies. Its lead product, the PoNS device, was authorized in Canada for certain multiple sclerosis and traumatic brain injury uses and received FDA marketing authorization in March 2021 for MS-related gait deficit. The company said U.S. commercial availability was not expected until Q1 2022. Financial amounts below are in U.S. dollars; statements of operations and cash flows are unaudited.
Financial results and liquidity
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Revenue | $109,000 | $131,000 | $264,000 | $470,000 |
| Gross profit | $23,000 | $109,000 | $95,000 | $283,000 |
| Gross margin | 21% | 83% | 36% | 60% |
| Operating expenses | $4.396 million | $3.769 million | $14.135 million | $11.667 million |
| Operating loss | $(4.373) million | $(3.660) million | $(14.040) million | $(11.384) million |
| Net loss | $(4.687) million | $(3.477) million | $(14.030) million | $(11.595) million |
| Operating cash used | Not presented quarterly | Not presented quarterly | $(9.925) million | $(9.567) million |
At September 30, 2021, cash was $4.7 million, working capital was $3.596 million, and total assets and liabilities were $7.879 million and $2.842 million, respectively. The balance sheet lists no conventional borrowings; operating lease liabilities totaled $47,000, all current. Cash increased $1.369 million over the first nine months, primarily because $11.353 million of financing cash inflows exceeded operating and investing cash use. Financing included the February 2021 stock-and-warrant offering and sales under the Lincoln Park equity purchase agreement.
Material changes versus comparable periods
- Nine-month revenue fell 44% year over year, primarily reflecting COVID-19 impacts on Canadian sales and pricing changes intended to lower upfront costs. Q3 revenue declined 17%.
- Nine-month operating expenses increased $2.468 million, led by higher selling, general and administrative costs, including stock-based compensation and added management and sales staff, as well as increased product development spending.
- Nine-month net loss widened by $2.435 million. In Q3, the loss widened by $1.210 million, including a $314,000 foreign-exchange loss versus a $182,000 gain a year earlier.
- Shares outstanding increased to 2,392,130 at September 30 from 1,484,362 at December 31, 2020, reflecting equity financing and other issuances. The February offering generated approximately $9.6 million net proceeds; Q3 Lincoln Park sales generated approximately $0.6 million net proceeds.
Outlook, risks and unusual items
- Going concern: Management stated that substantial doubt exists about the company’s ability to continue as a going concern within one year after filing. Based on the first nine months’ burn rate, it expected existing resources to fund operations into Q1 2022, while also anticipating higher pre-commercialization costs. Additional capital is required; success and terms are uncertain.
- Potential financing and dilution: Lincoln Park committed to purchase up to $15 million of common stock over 36 months, subject to conditions and limits. The facility is not guaranteed funding, and future sales may dilute shareholders.
- Commercial and reimbursement execution: The company was preparing for a U.S. launch, applied for unique HCPCS codes, and expected broad payer coverage and reimbursement to take at least 24 months. CMS proposed repealing the Medicare Coverage of Innovative Technology pathway; the filing describes the proposal, not a final outcome.
- Clinical and regulatory plans: The company planned a U.S. MS therapeutic experience program, with enrollment expected from late Q4 2021 through mid-2022. It also planned a pivotal stroke trial for Q2 2022. The filing reported Australian market authorization received in November 2021, after quarter-end, with scope still being finalized.
- Operating risks: COVID-19 restrictions and reduced clinic capacity, patient willingness, clinical enrollment, supplier and labor constraints, and manufacturing or shipping delays could impair Canadian sales and delay U.S. launch plans. Reliance on third-party manufacturers and distributors is also a stated risk.
- Unusual expenses and items: Q3 included $0.4 million of cash severance related to the former COO and approximately $0.5 million of accelerated stock-based compensation tied to that departure. Nine-month SG&A also included approximately $1.0 million of stock-based compensation for a one-time fully vested option grant to the then interim CEO. Foreign-exchange movements materially affected quarterly results.
Important facts for investors to verify
- Confirm the filing entity: the supplied document is Helius Medical Technologies, not Solana Co.
- Track cash burn, funding needs, and the conditions and actual proceeds available under the Lincoln Park facility; the company disclosed substantial going-concern doubt.
- Monitor U.S. launch timing, HCPCS coding, payer coverage, and the status of CMS’s proposed repeal of the MCIT pathway.
- Assess whether Canadian clinic activity, PoNS sales, and patient access recover from pandemic-related constraints, and whether manufacturing capacity supports commercialization.
- Review the impact of ongoing losses, equity issuance, warrants, stock-based compensation, and potential dilution on per-share value.